Click here to create your personal news page. The news that appears on DOR BioPharma will appear there and be constantly updated. You can then modify the page, share it with your friends, or export it and have it appear elsewhere.

You can also create a personal news page and follow the news that interests you by clicking on the tab labelled 'New page'.  

topics : related - allExplore

Wikio Shopping (beta)

  1. 1. Computers
  2. 2. Electronics
  3. 3. Communication
  4. 4. Household Appliances
  5. 5. Car/Motor Bike
  6. 6. Digital Camera
  7. 7. Mobile Phone
  8. 8. Smartphone
  9. 9. PDA
  10. 10. GPS
  11. 11. LCD Monitor
  12. 12. Printer

New products

  1. 1. Casio Exilim EX-Z85
  2. 2. Casio Exilim EX-Z250
  3. 3. Casio Exilim EX-Z300
  4. 4. Razer Megalodon
  5. 5. Asus P6T Deluxe
  6. 6. Onkyo TX-SR806
  7. 7. Microsoft Sidewinder X5
  8. go to Shopping

Participate

News Categories



DOR BioPharma


Sort by : relevance - date
6Vote!

DOR BioPharma, Inc.: DOR BioPharma Reports 2nd Quarter 2008 Financial Results

Market Wire (Free subscription) | 08/15/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company") today announced its financial results for the second quarter ended June 30, 2008.

+Vote!

DOR BioPharma, Inc.: DOR BioPharma Announces Initiation of Second Human Clinical Trial for RiVax(TM), Its Ricin Toxin Vaccine

Market Wire - Pharmaceuticals and Biotech: Drugs (Free subscription) | 08/07/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company, announced today that one of its academic development partners has initiated a second human clinical trial of RiVax™ in healthy volunteers. RiVax™ is a recombinant subunit vaccine designed to induce protection against exposure to ricin toxin, a category B biothreat. This...

+Vote!

DOR BioPharma Announces Initiation Of Second Human Clinical Trial For RiVaxTM, Its Ricin Toxin Vaccine

Medical News Today (Free subscription) | 08/08/2008

DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company, announced that one of its academic development partners has initiated a second human clinical trial of RiVax™ in healthy volunteers. RiVax™ is a recombinant subunit vaccine designed to induce protection against exposure to ricin toxin, a category B biothreat.

+Vote!

DOR BioPharma, Inc.: DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in Collaboration With Steward Cross Pte Ltd

Market Wire - Medical and Healthcare: Healthcare (Free subscription) | 07/18/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Steward Cross Pte Ltd (Steward Cross), a...

+Vote!

DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in Collaboration With Steward Cross Pte Ltd

Red Orbit (Free subscription) | 07/18/2008

DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Steward Cross Pte Ltd (Steward Cross), a specialty pharmaceutical company...

+Vote!

DOR BioPharma Announces Named Patient Access Program for orBec(R) in Singapore and Malaysia in Collaboration With Steward Cross Pte Ltd

The Earth Times Online Newspaper (Free subscription) | 07/18/2008

EWING, NJ -- 07/18/08 -- DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and v..

1Vote!

DOR BioPharma, Inc.: DOR BioPharma Enters Into Collaborative Agreement With IDIS for Named Patient Access of orBec(R) in Europe

Market Wire - Government: International (Free subscription) | 07/15/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments, serious gastrointestinal diseases and vaccines against certain bioterrorism agents, announced today that it has executed a definitive collaborative agreement with IDIS Limited ("IDIS"),...

+Vote!

DOR BioPharma, Inc.: DOR BioPharma Announces Collaboration With Numoda Corporation for the Execution of Confirmatory, Phase 3 Clinical Trial of orBec(R)

Market Wire (Free subscription) | 06/30/2008

EWING, NJ (MARKET WIRE) DOR BioPharma, Inc. (OTCBB: DORB) ("DOR" or the "Company"), a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has entered into a collaboration with Numoda Corporation (Numoda), experts in...